Gilead Sciences (GILD) : Bender Robert Associates reduced its stake in Gilead Sciences by 1.46% during the most recent quarter end. The investment management company now holds a total of 100,020 shares of Gilead Sciences which is valued at $8,656,731 after selling 1,477 shares in Gilead Sciences , the firm said in a disclosure report filed with the SEC on Jul 22, 2016.Gilead Sciences makes up approximately 5.78% of Bender Robert Associates’s portfolio.
Other Hedge Funds, Including , Goelzer Investment Management reduced its stake in GILD by selling 2,371 shares or 3.59% in the most recent quarter. The Hedge Fund company now holds 63,597 shares of GILD which is valued at $5,504,320. Gilead Sciences makes up approx 0.73% of Goelzer Investment Management’s portfolio.Clarkston Capital Partners reduced its stake in GILD by selling 25 shares or 1.02% in the most recent quarter. The Hedge Fund company now holds 2,425 shares of GILD which is valued at $209,884. Gilead Sciences makes up approx 0.01% of Clarkston Capital Partners’s portfolio.Eqis Capital Management boosted its stake in GILD in the latest quarter, The investment management firm added 4,415 additional shares and now holds a total of 70,469 shares of Gilead Sciences which is valued at $6,125,870. Gilead Sciences makes up approx 0.40% of Eqis Capital Management’s portfolio.R.h. Dinel Investment Counsel reduced its stake in GILD by selling 600 shares or 3.58% in the most recent quarter. The Hedge Fund company now holds 16,175 shares of GILD which is valued at $1,387,006. Gilead Sciences makes up approx 1.59% of R.h. Dinel Investment Counsel’s portfolio.Jacobs Coca boosted its stake in GILD in the latest quarter, The investment management firm added 380 additional shares and now holds a total of 33,940 shares of Gilead Sciences which is valued at $2,910,355. Gilead Sciences makes up approx 0.67% of Jacobs Coca’s portfolio.
Gilead Sciences closed down -1.77 points or -2.18% at $79.47 with 1,94,65,672 shares getting traded on Friday. Post opening the session at $80.6, the shares hit an intraday low of $79.37 and an intraday high of $80.84 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.